Thank you very much for the intro, and thank you, everyone out there who has an interest in CellaVision DI-60 for tuning in to hear our presentation for the second quarter. In our fiscal year 2025, I have our CFO, Magnus Blixt, with me, and we'll be pleased to present and discuss the report today. Um, the quarter in brief. Basically, we have categorized and labeled our report as presenting robust results with mixed regional performance. And so you can say it's a report where we are reporting 191 million SEK. Uh, top line. Uh, so it represents 2% growth equivalent to 7.8 or almost 8% organic growth given the headwind on the currency of around 6%. It's a report highlighting a quarter where we have had significant contributions from APAC with some truly exceptional contributions. And then we've had quarterly variations from the Americas and EMEA.
Given the nature of our business.
But I will try to unfold that as we progress.
First of all, a few highlights on the progress of our strategic directions while executing the Power of Focus strategy.
We actually have made progress on a number of things, with significant advancements on the internal lines. And this quarter, we want to highlight the progress we've made with the bone marrow module.
The bone marrow analysis and the clinical trials are very close to completion. And in fact, a number of the studies have been completed. We're continuing certain clinical validations in the US. Um, and here we are reporting pretty much as previously. And here we modify that and say at the beginning of 2026. However, this should still enable our commercial launch in Europe to begin in the beginning of 2026. So things are going according to plan.
Uh, a little bit out of our hands with regards to the actual review, um, which includes the work with the notified body, but good progress.
And it's been a privilege to follow the program.
And now we're really excited to see, and we expect to get the approval. Uh, so that is exciting for us. We're also in this quarter, as you know, those of you who have followed CellaVision DI-60, we have invested significantly in our R&D and development efforts.
And here we are highlighting that we're actually coming out with an upgraded software for our CellaVision DI-60, our integrated system with Sysmex. It contains both an improved user interface and several new features, but it also offers seamless integration with the Sysmex, uh, smearing and staining device SP-50. And it is now compatible with our methanol-free stain, which is our proprietary stain. Um, so this is a very important milestone on our journey towards the globalization of our reagent portfolio.
Um, so those were the really appropriate highlights to emphasize in this quarter. Let's go to the financial development.
Um, so on this somewhat busy slide, uh, but very organized slide, you see our Q2 results spelled out, uh, from a personal perspective, and you have comparison quarters, uh, from last year and year-to-date this year compared with the year-to-date last year. So I said organic growth of almost 8%, and a gross margin, which is higher compared to the comparable quarter last year, it's increased to 68%. Um, so we've had positive contributions, somewhat from price increases, but also negative contributions from FX. Um, we have operating expenses of 41%. As compared to sales, that's primarily due to a slightly higher burn rate in administration, complying with certain systems, regulatory-wise, and slightly increased R&D spending as well, according to our strategy. So that gives us an EBITDA of 60 million, which is comparable to the equivalent quarter, and an EBITDA margin of 31% in line with our corporate objectives.
It's 22%. It's increased from 19% to 22%. Um, and in actual numbers, we've spent 42 million versus 36 million last year in the comparable quarter. Um, so here we have approximately 22 million sitting in the P&L, and then we have 20 million capitalized versus last year, where we had 20 million sitting in the P&L and 16 million capitalized.
Cash flow-wise, we have an operating cash flow of 58 million this quarter. So we've had a positive contribution from our working capital, namely 7.5 million, primarily due to the fact that we've reduced accounts receivable and decreased our inventory. So that's kind of a shared contribution, if you like, on the investment side. So that leaves us with a total cash flow of -30 million this quarter, which is somewhat stronger than the comparable quarter last year.
Still a very healthy company from a financial perspective with hardly any debt.
And, um, we have cash and bank equivalents of 155 million sitting on the balance sheet as of today, as of this quarter. Let's try and unfold the regional highlights on the top line, looking at what happens in the Americas.
And, um. And APAC. As for the Americas, um. We had an organic growth of 5%. And so that was equivalent to 66 million. So, we had pretty healthy contributions from our integrated systems. The DI-60.
However, we had a softer contribution this quarter from our DC one instrument sales, catering to the smaller laboratories. Um, say our analysis is probably more related to internal matters on the diff line where we've been transitioning from one smearing device, where we've had issues, to a more simple smearing device. So, that has impacted the demand side. We still see continued progress in expanding our market presence in Latin America and especially in countries like Brazil, where we see attraction for the DC one instrument format. So, we were reporting 80 million here. Um, it's a little bit mixed, large and small. But what is good to hear is that there is actually momentum across multiple countries.
Uh, also when we have communication with our key partner, there are orders coming in from multiple countries. Um, but of course, there's a slight softness in order placement for installation. That is the nature of the process, balancing the time between receiving orders from the lab and the installation phase. Um, and then, uh, I can talk to APAC where I would say a very strong APAC 46 million organic growth equivalent to 27%.
Um, um, after the 5% currency effect there, um, there is a contribution, uh, sort of in general from APAC, but also an exceptional contribution.
Since strategically, we've been running a program where we are manufacturing the DI-60 out of China.
Um, and as part of that, um, process, we have shipped a number of, um, components, uh, going to the Made in China manufacturing line, which is what you also see in our numbers with an exceptionally high, um, contribution from APAC and especially to China. Um, but again the broad integrated solution is strong. And we have also, over the years, you can say, centralized and streamlined our commercial operations across APAC to really work closely with our key partner, Sysmex.
But we have actually also expanded in Southeast Asia with the resources to help us and Sysmex drive growth in the region. So we're still investing in sales and marketing. Also on the research side.
Yeah, this chart shows sales per product group, which is when we categorize the revenue into product categories: instruments, reagents, software, and others where others refer to our spare parts and oil consumables. Um, um, and here I think I already talked about the instrument dynamics. Uh, but in general this quarter, it is the large instruments that remain the significant driver. We do have some product mix within that category as well. Uh, but also across the small, um, instrument category, as I alluded to. Um, what I want to highlight on the reagents is especially for the EMEA, where we have 20% growth compared to the comparable quarter for hematology reagents. So, hematology reagents, and especially in EMEA where we have the majority of our sales, are really growing healthily, up double digits, which is in line with our strategy. And good to see again our reagent expansion, a strategic pillar, embraces both APAC and the US. However, it's still small numbers spread across multiple markets, but we are increasing with, um, from 1.5 to 1.8 and about a million in increase compared with 2.3 million last year, year to date and 3.2 now. So it's about a million we've grown year to date compared with the comparable quarter. So, that's of course smaller numbers. But the big driver in APAC is China, where we are working on our distribution setup to eventually get into China and combine that with our total offering. As the only solution provider who can deliver both instruments, reagents, and superior software. Um, and for the US, I should also mention that the MCDh is now available with our software upgrade. I think that is extremely strategically important; that milestone endorses our opportunity to bring MCDh both to Europe, and of course, also to the US, where we have a large opportunity to improve and deliver a much, much more environmentally friendly solution to the labs. So that is a key milestone that you will hear more about as we plan the big launch for autumn.
Um, yeah. And the remaining part around software is pretty much in line with our installed base and our instrument sales. So let's take the key takeaways.
It's a bit extensive. Um, but I'm actually pretty proud of what we are reporting on this slide again. Uh, we see, um, this mixed regional performance. Um, but we see organic growth. Uh, there is some, uh, let's call it not seasonality, but there is a function as to when we hear about orders at hospitals versus when we need to deliver. Um, and if I look at the power of our focus strategy, and I think about the strategic partnership that we have closed, we're continuing to renew and improve the way we work, especially in our marketing efforts. Uh, sales-wise, sales support-wise, but we're also increasing our engagement in the investment program and really making some progress. And I think these bullets speak to our progress. Uh, the clinical trials for bone marrow are now completed for Europe.
Uh, and we can really start to envision our CE Mark.
There is obviously uncertainty around when you file before you get the actual approval of your documentation. However, we are confident that we will have the CE mark by the beginning of 2026, leading to our launch.
I have introduced today, without explicitly announcing the actual launch and the content, but we're very proud and I'm very proud of the team who has achieved this improved software version that we will launch this year.
Um, and then I also want to emphasize that our R&D spending entails the adaptation of our superior Fourier Ptychographic Microscopy technology, which we are integrating into our core hematology business and developing as the next generation solution. So that is progressing according to plan.
Um, and the continued exploration of our FPM in adjacent fields such as pathology and cytology is also progressing, where we are continuously refining and improving the technology and engaging in external conversations about this superior and proprietary technology. So we do continue on our journey to push the limit of delivering cutting-edge solutions, reaffirming our market position in line with our strategic plan. So finally, I mean, before we go to the question and answers, I think it's a super special day for me, and not the least for Magnus.
Uh, our CFO, um, Magnus has decided to leave CellaVision DI-60 after 12 years.
Uh, so this is actually your final call. That's right. You've been there, almost sitting here 50 times, I guess. Um, um, but of course, I want to thank you so much for what you've done for the company, the journey you've been on from a very small to a mid-sized company, where we are on a very interesting trajectory. Uh, I think with your capabilities, you will have all opportunities, uh, going forward, but I, of course, want to thank you also in this community where you work closely with multiple investors, for everything you have done for the company. Um, so thanks, Magnus.